The results of combined conservative treatment after photoselective laser vaporization of the prostate gland over her benign hyperplasia
##plugins.themes.bootstrap3.article.sidebar##
##plugins.themes.bootstrap3.article.main##
Abstract
The objective: to evaluate the clinical efficacy of combined therapy with Serenoa repens extract (Prostamol Uno) and selective α-adrenoblocker (Flosin) in patients with BPH stage II III after performing Photoselective Laser Vaporization of the Prostate (PLVP).
Materials and methods. The patients were divided into four clinical groups. Patients in group 1 (n = 17) did not take medical treatment after FSLVP, follow up was established for them. Patients in the 2nd group (n = 28) received monotherapy with Prostamol Uno, which they took before bedtime 1 capsule daily for 3 years. Patients in 3rd group (n = 27) received Flosin in a dose of 0.4 mg, 1 capsule per day in the morning after eating for 3 years. Persons in the 4th group (n = 29) received combination therapy: Prostamol Uno 1 capsule per day before bedtime and Flosin in a dose of 0.4 mg, 1 capsule per day in the morning, after eating, for 3 years. The examination carried out in the period after 1 and 3 years.
Results. As a result of the study, it was found that the best results were observed in patients who received combined conservative therapy with Serenoa repens extract and tamsulosin after PLVP.
Conclusions. Rehabilitation in persons with BPH, who under went minimally invasive interventions PLVP require long term therapy with a combination of palm extract Sabal (Prostamol Uno) and selective α-blocker (Flosin). Combination therapy with Prostamol Uno and Floxin is pathogenetically highly effective and safe, which facilitates the rapid elimination of irritative and obstructive symptoms, with an improvement in the patient’s quality of life.
##plugins.themes.bootstrap3.article.details##
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors retain the copyright and grant the journal the first publication of original scientific articles under the Creative Commons Attribution 4.0 International License, which allows others to distribute work with acknowledgment of authorship and first publication in this journal.
References
Горпинченко И.И., Гурженко Ю.Н., Клименко П.М., Шуляк А.В., Спиридоненко В.В. Исследование Проспект 2 (ПРОСтамол: ПЕрспективы Комбинированной Терапии) при ДГПЖ // Здоровье мужчины. – 2012. – No 1. – С. 56–60.
Горпинченко І.І., Гурженко Ю.М., Спиридоненко В.В. Сучасні дані про вплив хронічного запалення в патогенезі доброякісної гіперплазії передміхурової залози і раку передміхурової залози // Здоровье мужчины. – 2014. – No 4. – С. 91–94.
Гурженко Ю.Н., Спиридоненко В.В., Гайсенюк Ф.З. Профилактика осложнений после оперативного вмешательства по поводу доброкачественной гиперплазии предстательной железы // Здоровье мужчины. – 2016. – No 3 (58). – С. 12–15.
Переверзев А.С., Сергиенко Н.Ф. Аденома предстательной железы. К, Здоровье. 1998. – 278 с.
Ситенко А.М «Фотоселективная лазерная вапоризация: анализ у пациентов с объемом опухоли >60 см3» Програма науково-практичної конференції «Актуальні питання сучасної сексології та андрології», м. Київ. 19.05.2016.
Aliaev I.G, Vinarov A.Z, Demidko I.L, Spivak L.G. The results of the 10 year study of efficacy and safety of Serenoa repens extract in patients at risk of progression of benign prostatic hyperplasia // Urologia. – 2013, Jul Aug; (4). – Р. 32–6.
Berges R.R., Pientka L., Hufner K. et al. Male lower urinary tract symptoms and related health care seeking in Germany // Eur. Urology. – 2001. – V. 39. – P. 682.
De Marzo A.M. Pathological and molecular mechanisms of prostate cancerogenesis: implications for diagnosis, prevention and treatment // J Cell Biochem. – 2004. – V. 91. – P. 459–477.
